Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Goldberg

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Opinion in Oncology|June 6, 2013
Immunotherapy of sarcomasJohn M Goldberg
Discovery Medicine|April 25, 2014
Immunotherapy in sarcoma: a new frontierBreelyn A Wilky, John M Goldberg
Discovery Medicine|March 1, 2017
From vision to reality: deploying the immune system for treatment of sarcomaBreelyn A Wilky, John M Goldberg
Journal of Pediatric Hematology/Oncology|May 16, 2012
Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemiaJohn M Goldberg, Rebecca E Scully, Stephen E Sallan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2014
Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinibJohn M Goldberg, Tara Gavcovich, Gaurav Saigal, et al.
Cancer Treatment Reviews|June 25, 2013
Active immunotherapy using dendritic cells in the treatment of glioblastoma multiformeAmade Bregy, Theresa M Wong, Ashish H Shah, et al.
Current Treatment Options in Oncology|May 16, 2015
Rhabdomyosarcoma in adults: new perspectives on therapyCatalina Ruiz-Mesa, John M Goldberg, Alvaro J Coronado Munoz, et al.
Journal of Oncology Practice|April 20, 2013
Clinical practice guidelines for cancer care: utilization and expectations of the practicing oncologistMelissa Dillmon, John M Goldberg, Suresh S Ramalingam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2003
Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experienceJohn M Goldberg, Lewis B Silverman, Donna E Levy, et al.
Cancer|May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trialAndrew J Wagner, John M Goldberg, Steven G Dubois, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Opinion in Oncology|June 6, 2013
Immunotherapy of sarcomasJohn M Goldberg
Discovery Medicine|April 25, 2014
Immunotherapy in sarcoma: a new frontierBreelyn A Wilky, John M Goldberg
Discovery Medicine|March 1, 2017
From vision to reality: deploying the immune system for treatment of sarcomaBreelyn A Wilky, John M Goldberg
Journal of Pediatric Hematology/Oncology|May 16, 2012
Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemiaJohn M Goldberg, Rebecca E Scully, Stephen E Sallan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2014
Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinibJohn M Goldberg, Tara Gavcovich, Gaurav Saigal, et al.
Cancer Treatment Reviews|June 25, 2013
Active immunotherapy using dendritic cells in the treatment of glioblastoma multiformeAmade Bregy, Theresa M Wong, Ashish H Shah, et al.
Current Treatment Options in Oncology|May 16, 2015
Rhabdomyosarcoma in adults: new perspectives on therapyCatalina Ruiz-Mesa, John M Goldberg, Alvaro J Coronado Munoz, et al.
Journal of Oncology Practice|April 20, 2013
Clinical practice guidelines for cancer care: utilization and expectations of the practicing oncologistMelissa Dillmon, John M Goldberg, Suresh S Ramalingam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2003
Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experienceJohn M Goldberg, Lewis B Silverman, Donna E Levy, et al.
Cancer|May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trialAndrew J Wagner, John M Goldberg, Steven G Dubois, et al.
Pageof 2